/
ENOV
$22.02-$0.69 (-3.04%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.3B
58M shares
52-week range
$20.55 – $36.82
9% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NYSE
CS
Price (6 mo)
Loading chart…
Change$-48.43
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.67B | $3.33B | $1.12B | $1.43B | $1.56B | $1.71B | $2.11B | $2.25B |
| Cost of revenue | $2.53B | $1.93B | $517.1M | $648.5M | $693.7M | $716.4M | $926.9M | $902.8M |
| Gross profit | $1.13B | $1.40B | $603.6M | $777.7M | $869.4M | $990.8M | $1.18B | $1.35B |
| Gross margin | 30.9% | 42.1% | 53.9% | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| R&D | $34.2M | $0 | $34.3M | $49.1M | $60.8M | $75.3M | $91.3M | $120.3M |
| Operating income | $236.9M | $203.6M | −$66.2M | −$62.8M | −$71.2M | −$65.7M | −$775.7M | −$18.9M |
| EBITDA | $330.3M | $406.0M | $180.0M | $170.3M | $241.7M | $169.7M | −$481.0M | −$830.2M |
| Net income | $140.2M | −$527.6M | $42.6M | $71.7M | −$13.3M | −$33.3M | −$825.5M | −$1.18B |
| Net margin | 3.8% | -15.9% | 3.8% | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (diluted) | 3.48 | 0.41 | 1.11 | -2.02 | -0.28 | -0.61 | -14.93 | -20.86 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.3B | $3.65 | $3.62–$3.67 | 6 |
| 2027 | $2.5B | $4.08 | $4.02–$4.12 | 6 |
| 2028 | $2.6B | $4.48 | $3.34–$5.62 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Enovis Corporation
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
www.enovis.com- Employees
- 7,802
- IPO / List date
- May 8, 2008
- HQ
- WILMINGTON, DE
Held by traders on TradeandTell
No one on the platform currently holds ENOV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 75,967 | $2.4M |
| Bridgewater Associatesas of 2026-03-31 | 51,224 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ENOV yet.
